Sabra Healthcare SBRA Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Net margin | 19.2%-0.9pp | 20.1%-3.4pp | 23.5%-1.4pp | 24.9%+5.3pp | 19.5%+1.5pp | |
| Returns | ||||||
| Return on equity | 5.7%+0.1pp | 5.6%-0.7pp | 6.3%-0.4pp | 6.7%+1.5pp | 5.1%+0.6pp | |
| Return on invested capital | 9.8%+0.1pp | 9.6%-1.0pp | 10.7%-0.3pp | 10.9%+1.5pp | 9.4%+0.5pp | |
| Efficiency | ||||||
| Asset turnover | 0.2×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | |
| Leverage | ||||||
| Debt-to-equity | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Net debt / EBITDA | -0.2×-0.1× | -0.1×+0.3× | -0.4×-0.2× | -0.2×-0.2× | -0×+0.1× | |
| Per Share | ||||||
| Book value per share | $10.88-5.7% | $11.54-0.5% | $11.60+3.1% | $11.25+0.1% | $11.25-3.2% | |
| Valuation | ||||||
| Market capitalization | $4.85B+2.7% | $4.72B+5.7% | $4.47B+1.4% | $4.41B+6.1% | $4.16B+1.4% | |
| Price / earnings | 31×+0.7× | 30.3×+4.8× | 25.5×+1.3× | 24.2×-5.3× | 29.5×-2.8× | |
| Price / sales | 6×-0.1× | 6.1×+0.1× | 6×0.0× | 6×+0.2× | 5.8×-0.1× | |
| Price / book | 1.7×+0.1× | 1.7×+0.1× | 1.6×0.0× | 1.6×+0.1× | 1.5×0.0× | |
| EV / EBITDA | 10.2×0.0× | 10.3×+1.1× | 9.2×0.0× | 9.3×-0.5× | 9.7×-0.1× | |
| Dividend yield | 6.1%-0.1pp | 6.1%-0.3pp | 6.4%-0.1pp | 6.4%-0.3pp | 6.8%-0.1pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Sabra Healthcare's ratios come from?
- Every ratio is computed from Sabra Healthcare's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
